Other
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value
AbbVie Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value increased by 6.6% to $27.04B in Q1 2026 compared to the prior quarter. This increase may warrant attention — for this metric, lower values are generally preferred.
Analysis
StatementBalance Sheet Statement
SectionOther
CategoryRisk
SignalLower is better
VolatilityModerate
First reportedQ4 2024
Last reportedQ1 2026May 8, 2026
How to read this metric
A high proportion of Level 3 liabilities suggests higher valuation risk and potential for future adjustments to the financial statements.
Detailed definition
This represents the value of liabilities measured using Level 3 inputs, which are unobservable and rely on the company's...
Peer comparison
Varies significantly; financial services and tech firms with complex derivatives or earn-outs will have higher levels than standard industrial firms.
Metric ID:
other_fair_value_measurement_with_unobservable_inputs_re_2a44fdHistorical Data
4 periods
| Q4 '24 | Q1 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|
| Value | $21.67B | $22.71B | $25.37B | $27.04B |
| QoQ Change | — | +4.8% | +11.7% | +6.6% |
| YoY Change | — | — | +17.1% | +19.0% |
Range$21.67B – $27.04B
Avg YoY Growth+18.1%
Median YoY Growth+18.1%
Current Streak3+ quarters growth
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value at Other Companies
Frequently Asked Questions
- What is AbbVie's fair value, measurement with unobservable inputs reconciliation, recurring basis, liability value?
- AbbVie (ABBV) reported fair value, measurement with unobservable inputs reconciliation, recurring basis, liability value of $27.04B in Q1 2026.
- What does fair value, measurement with unobservable inputs reconciliation, recurring basis, liability value mean?
- The value of liabilities calculated using internal estimates rather than market prices.